10 February 2011
A statement of the National Institute of Health and Welfare of Finland indicated an increased risk of narcolepsy among children and adolescents vaccinated with Pandemrix®, an adjuvanted vaccine against pandemic influenza A(H1N1) 2009 manufactured by GlaxoSmithKline. WHO’s Global Advisory Committee on Vaccine Safety (GACVS) has reviewed the data and released a statement.
01 February 2010
The National Institute of Health and Welfare of Finland today issued a statement indicating an increased risk of narcolepsy (a rare sleep disorder that causes a person to fall asleep suddenly and unexpectedly) observed among children and adolescents vaccinated with Pandemrix®, an adjuvanted pandemic H1N1 vaccine manufactured by GlaxoSmithKline.
14 January 2011
Influenza activity is increasing in the WHO European Region, most notably in the north-western part. Several countries have reported severe and fatal cases and the burden of severe influenza has placed considerable strain on critical care services in two western European countries.
17 December 2010
Signs of increasing influenza activity in a number of countries indicate the start of the influenza season in the WHO European Region.
15 May 2010
In the period May to June 2010, six randomly selected countries in the European Region will be visited by a WHO team of experts in pandemic preparedness and response.
24 February 2010
Based on available epidemiological and virological data provided to WHO between September 2009 and February 2010, WHO has announced the recommended viruses for use in the influenza vaccine for the 2010-2011 northern hemisphere influenza season.
17 November 2009
2 November 2009
1 November 2009